How much funding has Simcha Therapeutics raised?

Simcha Therapeutics has raised $65.0M in total funding, most recently a Series B round.

Who are Simcha Therapeutics's investors?

Simcha Therapeutics's investors include SR One, BVF Partners, Samsara BioCapital, Rock Springs Capital.

Where is Simcha Therapeutics headquartered?

Simcha Therapeutics is headquartered in New Haven, Connecticut, United States.

What industry is Simcha Therapeutics in?

Simcha Therapeutics operates in Biotech, Healthcare.

How many employees does Simcha Therapeutics have?

Simcha Therapeutics has 11-50 employees.

Simcha Therapeutics

Pioneering Transformational Immunotherapies

New Haven, United States · $65.0M raised

Biotech

Healthcare

Headquarters: New Haven, Connecticut
Employees: 11–50
Business Model: B2B
Website: simchatx.com

Total Funding: $65.0M
Last Round: $40.0M Series BJan 2022
Rounds: 2

About

Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics for cancer. The company's name derives from the Hebrew word for joy, reflecting its mission to advance medicines that bring hope to patients with cancer. Simcha focuses on transforming fundamental discoveries in immune biology into innovative drugs that promise more than incremental advances.

Summary

Simcha Therapeutics is a Biotech company based in New Haven, United States. It has raised $65.0M in total across 2 rounds, most recently a $40.0M Series B round in Jan 2022. Investors include SR One, BVF Partners and Samsara BioCapital.